Actively Recruiting
The Real-world Treatment Patterns and Clinical Outcomes in Moderate-to-severe Atopic Dermatitis Patients Receiving Abrocitinib
Led by Pfizer · Updated on 2025-09-03
200
Participants Needed
8
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating real-world treatment patterns and clinical outcomes in patients aged 12 years and older with moderate-to-severe atopic dermatitis who are receiving abrocitinib. The study aims to describe patient demographics and baseline characteristics over a 12-month observation period to better understand how abrocitinib is used in usual clinical practice conditions. Participants will be newly prescribed abrocitinib as decided by their physician during routine care. The study does not involve experimental treatments but observes how abrocitinib is used and its effects in everyday settings. There are no comparator groups or placebo treatments since this is an observational study. During the 12-month observation, researchers will track improvements in eczema severity using measures like the Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), and patient-reported outcomes such as the Peak Pruritus Numerical Rating Scale (PP-NRS). Data on treatment duration, quality of life, and symptom changes will also be collected. Patients' progress will be monitored at multiple time points including weeks 2, 4, 12, 16, 24, and 52.
CONDITIONS
Brief Title
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 12 years or older
- Confirmed diagnosis of moderate-to-severe atopic dermatitis by a physician
- Newly prescribed abrocitinib as part of usual clinical practice
- Signed informed consent or assent indicating understanding of the study
You will not qualify if you...
- Prior use of abrocitinib
- Currently participating in another study involving investigational drugs or procedures simultaneously with this study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 months
Participants receiving abrocitinib as part of routine clinical practice are observed to understand treatment patterns and clinical outcomes.
Visits at baseline, Week 2, 4, 12, 16, 24, and 52
Trial Site Locations
Total: 8 locations
1
Kaohsiung Medical University Hospital
Kaohsiung City, Taiwan, 807377
Not Yet Recruiting
2
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung City, Taiwan, 83301
Actively Recruiting
3
Taipei Medical University - Shuang Ho Hospital
New Taipei City, Taiwan, 23561
Not Yet Recruiting
4
NTUH
Taipei, Taiwan, 100
Actively Recruiting
5
MacKay Memorial Hospital
Taipei, Taiwan, 10449
Not Yet Recruiting
6
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Not Yet Recruiting
7
Tri-Service General Hospital
Taipei, Taiwan, 11490, R.O.C.
Not Yet Recruiting
8
Chang Gung Hospital Linkou
Taoyuan, Taiwan, 333
Not Yet Recruiting
Research Team
P
Pfizer CT.gov Call Center
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here